首页 正文

Cancer combinatorial immunotherapy using etigilimab and nivolumab: a patent evaluation of WO2018102536

{{output}}
Introduction: TIGIT is an inhibitory receptor expressed by lymphocytes that suppresses the immune response against tumor cells. There is a great need to discover and develop new therapies focused on inhibiting the action of TIGIT and consequently improving the... ...